© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Implications for treating patients with progressive, unresectable locally advanced or metastatic HER2-positive breast cancer with tucatinib in combination with capecitabine and trastuzumab.
September 8th 2021
Current treatment options and outcomes for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy, with special insight regarding the management of brain metastasis and visceral disease.
An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer.
Factors that impact treatment selection for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy.
Novel therapies that show promise in addressing treatment gaps in HER2-positive breast cancer, and exciting data that are expected to be reported on at the upcoming ESMO 2021 meeting.